# Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

> **NCT06561048** · PHASE3 · RECRUITING · sponsor: **Corvus Pharmaceuticals, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Follicular T-Cell Lymphoma
- Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
- Systemic Anaplastic Large Cell Lymphoma
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell

## Interventions

- **DRUG:** Soquelitinib
- **DRUG:** Belinostat
- **DRUG:** Pralatrexate

## Key facts

- **NCT ID:** NCT06561048
- **Lead sponsor:** Corvus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-02
- **Primary completion:** 2027-11
- **Final completion:** 2028-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561048, "Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06561048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*